At the time of writing, Bio-Rad Laboratories Inc [BIO] stock is trading at $284.6, up 17.63%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIO shares have gain 7.73% over the last week, with a monthly amount glided 13.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Rad Laboratories Inc [NYSE: BIO] stock has seen the most recent analyst activity on October 01, 2024, when Citigroup upgraded its rating to a Buy and also boosted its price target to $400 from $350. Previously, Wells Fargo started tracking the stock with Equal Weight rating on August 28, 2024, and set its price target to $340. Citigroup downgraded its rating to a Neutral and decreased its price target to $365 on April 03, 2024. UBS initiated its recommendation with a Buy and recommended $395 as its price target on December 07, 2023. Wells Fargo started tracking with a Overweight rating for this stock on June 16, 2023, and assigned it a price target of $550. In a note dated December 07, 2022, RBC Capital Mkts initiated an Outperform rating and provided a target price of $565 on this stock.
For the past year, the stock price of Bio-Rad Laboratories Inc fluctuated between $211.43 and $387.99. Currently, Wall Street analysts expect the stock to reach $482.5 within the next 12 months. Bio-Rad Laboratories Inc [NYSE: BIO] shares were valued at $284.6 at the most recent close of the market. An investor can expect a potential return of 69.54% based on the average BIO price forecast.
Analyzing the BIO fundamentals
According to Bio-Rad Laboratories Inc [NYSE:BIO], the company’s sales were 2.55B for trailing twelve months, which represents an 2.06% jump. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.12%. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 273.07 points at the first support level, and at 261.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 294.00, and for the 2nd resistance point, it is at 303.40.
Ratios To Look Out For
It is important to note that Bio-Rad Laboratories Inc [NYSE:BIO] has a current ratio of 5.12. Also, the Quick Ratio is 3.67. Considering the valuation of this stock, the price to sales ratio is 2.93, the price to book ratio is 1.08 and price to earnings (TTM) ratio is 24.25.
Transactions by insiders
Recent insider trading involved Crowley Michael, EVP, GBL Commercial Operations, that happened on Mar 14 ’25 when 3000.0 shares were sold. Officer, Crowley Michael completed a deal on Mar 13 ’25 to buy 3000.0 shares. Meanwhile, Director Alles Institute for Medical Re bought 410.0 shares on Mar 11 ’25.
